Atherosclerotic Cardiovascular Disease
📧 Sign up to get email alerts when something new happens for Atherosclerotic Cardiovascular Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction [Phase 2]
Phase IIa clinical trial update for YN001 targeting atherosclerotic cardiovascular disease and erectile dysfunction; the study is currently …
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects [Phase 1]
Phase 1 clinical trial assessing the safety and pharmacokinetics of the novel drug YN001 in combination with Rosuvastatin in healthy Chinese…
-
CLINICAL_TRIALS trial_result · 2025-12-29Clinical Trial Update: Lipoprotein (a) and Vascular Regenerative Cell Content
This clinical trial update indicates completion of a study examining lipoprotein(a) and vascular regenerative cell content sponsored by the …
-
CLINICAL_TRIALS research · 2025-12-12Clinical Trial Update: Fish Oil, Metformin and Heart Health in PCOS [Phase 1]
Phase 1 clinical trial assessing the effects of fish oil and metformin on cardiovascular health in PCOS; currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease [Phase 3]
A Phase 3 randomized trial to evaluate the effects of inclisiran on clinical outcomes in people with atherosclerotic cardiovascular disease;…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks
This clinical trial investigates the long-term effect of remote ischemic conditioning on major organs in patients with very high-risk athero…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists
A completed study assessing awareness and perceptions of systemic inflammation and hsCRP as biomarkers among Chinese cardiologists and nephr…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Evaluation of the Association Between the Effects of Generalized Stage 3 and 4 Periodontitis on Arterial Stiffness and Cardiovascular Risk: the PAROCAR Study [NA]
This clinical trial update describes the PAROCAR study evaluating whether generalized stage 3-4 periodontitis influences arterial stiffness …
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: Barriers to Optimal LDL-C Targets in Patients With Atherosclerotic Cardiovascular Disease
This completed clinical trial investigates barriers to achieving target LDL-C levels in patients with coronary artery disease and other athe…
-
CLINICAL_TRIALS trial_result · 2025-11-25Clinical Trial Update: A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease. [Phase 1]
A Phase 1b study evaluating AZD4144 in participants with established atherosclerotic cardiovascular disease and chronic kidney disease has c…
-
FDA label_change · 2025-11-21FDA Approved: NEXLIZET — Supplemental Application (Esperion Therapeutics, Inc.)
FDA approved a supplemental application for NEXLIZET (bempedoic acid and ezetimibe) to update/expand its labeling.
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability [Phase 3]
Phase 3 trial update evaluating bempedoic acid versus statins in primary-prevention patients with suboptimal statin adherence, focusing on L…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Evaluating Atherosclerotic Disease Progression in Patients With Diabetes Mellitus
A clinical trial is evaluating atherosclerotic disease progression in patients with Type 2 diabetes mellitus and coronary artery disease; re…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Low- and Moderate-intensity Statin and Clinical Outcome of Primary Prevention in Individuals Aged >70 Years: the SCOPE-70 RCT Study [Phase 4]
Clinical trial update on the SCOPE-70 Phase 4 study evaluating low- and moderate-intensity statin therapy for primary prevention in adults o…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial [NA]
A randomized Ez-PAVE trial in patients with atherosclerotic cardiovascular disease compares LDL-C targets of <70 mg/dL versus <55 mg/dL usin…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events [Phase 2]
Phase 2 study evaluating HRS-5346 in adults with elevated lipoprotein(a) at high cardiovascular risk has completed.
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
This clinical trial update describes routine validation and reproducibility testing of laboratory assays and techniques used in endocrine, c…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease [Phase 4]
Clinical trial update for VictORION-INCLUSION, a Phase 4 study evaluating inclisiran for cholesterol management in patients with atheroscler…
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)
A completed trial comparing tirzepatide to sitagliptin in adults with type 2 diabetes and cardiovascular risk evaluates comparative effectiv…
-
CLINICAL_TRIALS research · 2025-10-27Clinical Trial Update: A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) [NA]
An observational cross-sectional study updating lipoprotein(a) levels in patients with a documented history of atherosclerotic cardiovascula…
-
FDA label_change · 2025-10-09FDA Approved: PRALUENT — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
FDA approved a supplemental application for PRALUENT (alirocumab) submitted by Regeneron, resulting in changes to the product labeling.
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies [Phase 3]
Phase 3 study evaluating a fixed-dose combination of obicetrapib and ezetimibe added to existing lipid-modifying therapy has completed. Resu…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Management
This clinical trial update describes the evaluation of an integrated, digital, nurse-led remote monitoring pathway for cardiovascular risk m…
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies
Completed analyses from UK Biobank and a Chinese single-center database suggest that use of 5-alpha reductase inhibitors may be associated w…
-
CLINICAL_TRIALS withdrawal · 2025-09-26Clinical Trial Update: Immunomodulatory Effects of PCSK9 Inhibition
A clinical trial examining the immunomodulatory effects of PCSK9 inhibition for cardiovascular disease has been withdrawn.